Metabolic  (dysfunction) associated fatty liver disease (MAFLD) is now the most common  cause of chronic liver disease worldwide with a global estimated prevalence of  25%1 ; this is linked to the increasing global incidence of type 2 diabetes  mellitus (T2DM) and obesity.
    Researchers  undertook the study to assess the effects of a 12-week aerobic exercise  intervention on histological and cardiometabolic endpoints in MAFLD. Exercise  is known to be beneficial for the treatment and prevention of many chronic  inflammatory diseases such as cancer, T2DM, arthritis and CVD.10-12 However,  the independent role of exercise in the treatment of MAFLD remains unclear.
    The  primary objective of this study was to determine the independent effects of  exercise alone, specifically 12 weeks of moderate-to-vigorous intensity aerobic  exercise, without prescribed dietary modifications, on histological endpoints  of MAFLD. Secondary objectives included: determining the impact of the exercise  intervention on cardiorespiratory fitness, physical activity levels and  measures of cardiometabolic health including body composition, vascular health,  glucose and lipid metabolism and circulating inflammatory markers. The final  objective was to determine the sustainability of the exercise intervention at  12 weeks and 52 weeks post-exercise intervention completion.
    Patients  with biopsy-confirmed MAFLD participated in a 12-week aerobic exercise  intervention were included in the study. Liver histology, cardiorespiratory  fitness (estimated V̇ O2max), physical activity, anthropometry and biochemical  markers were assessed at baseline, intervention completion, and 12 and 52 weeks  after intervention completion.
    On analysis, the following facts emerged.
    - Twenty-four patients completed the  exercise intervention (exercise group n = 16, control group n = 8). 
- In the exercise group, 12 weeks of aerobic  exercise reduced fibrosis and hepatocyte ballooning by one stage in 58% (P =  0.034) and 67% (P = 0.020) of patients, with no changes in steatosis (P =  1.000), lobular inflammation (P = 0.739) or NAFLD activity score (P = 0.172). 
- Estimated V̇ O2max increased by 17%  compared to the control group (P = 0.027) but this level of improvement was not  maintained at 12 or 52 weeks after the intervention. 
- Patients with fibrosis and ballooning  improvement increased estimated V̇ O2max by 25% (P = 0.020) and 26% (P =  0.010), respectively.
-  Anthropometric reductions including body mass  (P = 0.038), waist circumference (P = 0.015) and fat mass (P = 0.007) were also  observed, but no patient achieved 7%-10% weight loss.
"This pilot study paves  the way for larger randomised controlled trials to investigate the effects of  aerobic exercise on histological features of MAFLD, with a particular focus on  determining strategies to transition exercise into the community setting in  order to promote lifelong adherence to exercise therapy."wrote the team.
    Primary  source: Alimentary Pharmacology  & Therapeutics
    For full article follow the link:  doi:10.1111/apt.15989
 
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.